Journal article
Bispecific antibodies in cancer therapy
Current Opinion in Immunology, Vol.11(5), pp.558-562
1999
DOI: 10.1016/S0952-7915(99)00015-1
PMID: 10508714
Abstract
Based upon
in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition, molecular engineering approaches are providing new and improved sources of clinically relevant bispecific antibodies.
Details
- Title: Subtitle
- Bispecific antibodies in cancer therapy
- Creators
- David M Segal - National Institutes of HealthGeorge J Weiner - University of IowaLouis M Weiner - Fox Chase Cancer Center
- Resource Type
- Journal article
- Publication Details
- Current Opinion in Immunology, Vol.11(5), pp.558-562
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/S0952-7915(99)00015-1
- PMID
- 10508714
- ISSN
- 0952-7915
- eISSN
- 1879-0372
- Language
- English
- Date published
- 1999
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359937502771
Metrics
31 Record Views